Drug Trial Radar · NCT07186387
Study of LW402 in Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
144
Actual
Start
May 11, 2023
Primary completion
Sep 25, 2024
Study completion Feb 13, 2025
Sponsor
- Lead sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double blind, placebo-controlled phase 2 study to evaluate the efficacy, safety, PK and PD ofLW402 in patients with moderate-to-severe atopic dermatitis.
Conditions
- Atopic Dermatitis (AD)
Interventions
LW402Drug
LW402 tablets
LW402 placeboDrug
LW402 placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving EASI-50 at week 12Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.